Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 181

1.

Improved Central Nervous System Symptoms in People with HIV without Objective Neuropsychiatric Complaints Switching from Efavirenz to Rilpivirine Containing cART.

Vera JH, Bracchi M, Alagaratnam J, Lwanga J, Fox J, Winston A, Boffito M, Nelson M.

Brain Sci. 2019 Aug 9;9(8). pii: E195. doi: 10.3390/brainsci9080195.

2.

Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment.

Underwood J, De Francesco D, Cole JH, Caan MWA, van Zoest RA, Schmand BA, Sharp DJ, Sabin CA, Reiss P, Winston A; COmorBidity in Relation to AIDS (COBRA) Collaboration and the Pharmacokinetic and clinical Observations in PePle over fiftY (POPPY) Study Group .

Open Forum Infect Dis. 2019 May 3;6(6):ofz198. doi: 10.1093/ofid/ofz198. eCollection 2019 Jun.

3.

Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV.

De Francesco D, Underwood J, Bagkeris E, Anderson J, Williams I, Vera JH, Post FA, Boffito M, Johnson M, Mallon PWG, Winston A, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study.

AIDS. 2019 Oct 1;33(12):1871-1880. doi: 10.1097/QAD.0000000000002293.

PMID:
31259766
4.

Cognitive function, depressive symptoms and syphilis in HIV-positive and HIV-negative individuals.

De Francesco D, Winston A, Underwood J, Cresswell FV, Anderson J, Post FA, Williams I, Mallon PW, Sachikonye M, Babalis D, Vera JH, Bagkeris E, Milinkovic A, Sabin CA.

Int J STD AIDS. 2019 Apr;30(5):440-446. doi: 10.1177/0956462418817612. Epub 2019 Jan 10.

PMID:
30999830
5.

Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment.

Alagaratnam J, Dilly-Penchala S, Challenger E, Else L, Legg K, Petersen C, Jones B, Kulasegaram R, Seyedkazemi S, Lefebvre E, Khoo S, Winston A.

Br J Clin Pharmacol. 2019 May;85(5):1039-1040. doi: 10.1111/bcp.13878. Epub 2019 Mar 4. No abstract available.

PMID:
30834549
6.

Polypharmacy and drug-drug interactions in older and younger people living with HIV: the POPPY study.

Halloran MO, Boyle C, Kehoe B, Bagkeris E, Mallon P, Post FA, Vera J, Williams I, Anderson J, Winston A, Sachikonye M, Sabin C, Boffito M.

Antivir Ther. 2019;24(3):193-201. doi: 10.3851/IMP3293.

PMID:
30700636
7.

Magnetic Resonance Imaging of Cerebral Small Vessel Disease in Men Living with HIV and HIV-Negative Men Aged 50 and Above.

Haddow LJ, Sudre CH, Sokolska M, Gilson RC, Williams IG, Golay X, Ourselin S, Winston A, Sabin CA, Cardoso MJ, Jäger HR; Pharmacokinetics and clinical Observations in PeoPle over fiftY (POPPY) Study Group.

AIDS Res Hum Retroviruses. 2019 May;35(5):453-460. doi: 10.1089/AID.2018.0249. Epub 2019 Feb 20.

PMID:
30667282
8.

Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir.

Keegan MR, Winston A, Higgs C, Fuchs D, Boasso A, Nelson M.

J Neurovirol. 2019 Feb;25(1):85-90. doi: 10.1007/s13365-018-0688-3. Epub 2018 Nov 26.

9.

Patterns of Co-occurring Comorbidities in People Living With HIV.

De Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, Winston A, Reiss P, Sabin CA; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study and the AGEhIV Cohort Study.

Open Forum Infect Dis. 2018 Oct 24;5(11):ofy272. doi: 10.1093/ofid/ofy272. eCollection 2018 Nov.

10.

Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial.

Tan DHS, Raboud JM, Szadkowski L, Grinsztejn B, Madruga JV, Figueroa MI, Cahn P, Barton SE, Clarke A, Fox J, Zubyk W, Walmsley SL; VALIDATE Study Group .

J Antimicrob Chemother. 2019 Feb 1;74(2):480-488. doi: 10.1093/jac/dky433.

11.

Do people living with HIV experience greater age advancement than their HIV-negative counterparts?

De Francesco D, Wit FW, Bürkle A, Oehlke S, Kootstra NA, Winston A, Franceschi C, Garagnani P, Pirazzini C, Libert C, Grune T, Weber D, Jansen EHJM, Sabin CA, Reiss P; the Co-morBidity in Relation to AIDS (COBRA) Collaboration.

AIDS. 2019 Feb 1;33(2):259-268. doi: 10.1097/QAD.0000000000002063.

12.

Pain in people living with HIV and its association with healthcare resource use, well being and functional status.

Sabin CA, Harding R, Bagkeris E, Nkhoma K, Post FA, Sachikonye M, Boffito M, Anderson J, Mallon PWG, Williams I, Vera J, Johnson M, Babalis D, Winston A.

AIDS. 2018 Nov 28;32(18):2697-2706. doi: 10.1097/QAD.0000000000002021.

PMID:
30289809
13.

Self-management Interventions for Pain and Physical Symptoms Among People Living With HIV: A Systematic Review of the Evidence.

Nkhoma K, Norton C, Sabin C, Winston A, Merlin J, Harding R.

J Acquir Immune Defic Syndr. 2018 Oct 1;79(2):206-225. doi: 10.1097/QAI.0000000000001785.

PMID:
30212435
14.

Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor Monotherapy.

Haddow LJ, Godi C, Sokolska M, Cardoso MJ, Oliver R, Winston A, Stöhr W, Clarke A, Chen F, Williams IG, Johnson M, Paton N, Arenas-Pinto A, Golay X, Jäger HR.

Clin Infect Dis. 2019 Mar 5;68(6):1031-1040. doi: 10.1093/cid/ciy617.

PMID:
30084882
15.

Chronic Kidney Disease Risk in African and Caribbean Populations With HIV.

Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA, Post FA; UK CHIC Study.

J Infect Dis. 2018 Oct 20;218(11):1767-1772. doi: 10.1093/infdis/jiy397.

16.

Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study.

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Stephan C, Rockstroh J, Giacomelli A, Vera J, Bernardino JI, Winston A, Saumoy M, Gras J, Katlama C, Pozniak AL; European Network for AIDS Treatment 022 (NEAT022) Study Group .

Clin Infect Dis. 2019 Feb 1;68(4):597-606. doi: 10.1093/cid/ciy505.

PMID:
29912307
17.

Clinical research cerebral MRI findings in HIV-positive subjects and appropriate controls.

Chhabra S, Underwood J, Cole JH, Caan M, Waldman A, Reiss P, Sabin CA, Sharp DJ, Winston A; CoBRA collaboration.

AIDS. 2018 Sep 10;32(14):2077-2081. doi: 10.1097/QAD.0000000000001910.

PMID:
29912060
18.

Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fiftY (POPPY) study.

Bagkeris E, Burgess L, Mallon PW, Post FA, Boffito M, Sachikonye M, Anderson J, Asboe D, Garvey L, Vera J, Williams I, Johnson M, Babalis D, De Francesco D, Winston A, Sabin CA.

Int J Epidemiol. 2018 Oct 1;47(5):1391-1392e. doi: 10.1093/ije/dyy072. No abstract available.

19.

Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C, Martin F, Cane P; UK HIV Drug Resistance Database; UK Collaborative HIV Cohort.

AIDS Res Ther. 2018 Apr 16;15(1):11. doi: 10.1186/s12981-018-0198-7.

20.

Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment.

Underwood J, De Francesco D, Leech R, Sabin CA, Winston A; Pharmacokinetic and Clinical Observations in PeoPle Over fiftY (POPPY) study.

PLoS One. 2018 Apr 11;13(4):e0194760. doi: 10.1371/journal.pone.0194760. eCollection 2018.

Supplemental Content

Loading ...
Support Center